Cornerstone Therapeutics, Inc. (CRTX) Tops Q2 EPS by 5c, Revenues Beat Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CRTX Hot Sheet
Price: $1.95 --0%
Financial Fact:
Total costs and expenses: 37.66M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Total costs and expenses: 37.66M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Cornerstone Therapeutics, Inc. (NASDAQ: CRTX) reported Q2 adjusted EPS of $0.11, $0.05 better than the analyst estimate of $0.06. Revenue for the quarter came in at $28.04 million versus the consensus estimate of $25.71 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
- Infosys Limited (INFY) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
